香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不會就本通告全部或任何部分內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 Kangji Medical Holdings Limited （於開曼群島註冊成立的有限公司） 康基医疗控股有限公司 董事會會議通告 康 基 醫 療 控 股 有 限 公 司（「本公司」）董 事 會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零 二 五 年 八 月 二 十 八 日（星 期 四）舉 行 董 事 會 會 議，藉 以（其 中 包 括） 考慮及批准本公司及其附屬公司截至二零二五年六月三十日止六個月 的 中 期 業 績 及 其 發 佈，以 及 考 慮 派 付 中 期 股 息 的 建 議（如 有）。 承董事會命 康 基 醫 療 控股有限公司 董事長 鍾 鳴 中 國，杭 州，二 零 二 五 年 八 月 十 五 日 於 本 通 告 日 期，董 事 會 包 括 執 行 董 事 鍾 鳴 先 生、申 屠 銀 光 女 士 及 尹 自 ...

2025 年 8 月 15 日 註： J.P. Morgan Securities PLC 是與要約人有關連的第(5)類別聯繫人。 | 交易方 | 日期 | 有關證券的說 | 交易性質 | 買入／賣出 | 涉及的股份 | 已支付／已收 | 已支付或已 | 已支付或已 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 明 | | | 總數 | 取的總金額 | 收取的最高 | 收取的最低 | | | | | | | | | 價（H） | 價（L） | | J.P. Morgan | 2025年8月14 | 其他類別的證 | 因全屬客戶主動發出且由客戶需求帶動的買賣 | 買入 | 30,500 | $262,471.5100 | $8.7000 | $8.5100 | | Securities | 日 | 券 (例如: 股 權互換) | 盤所產生的 Delta 1 產品的對沖活動 | | | | | | | PLC | | 其他類別的證 | 因全屬客戶主動發出且由客戶需求帶動的買賣 | 買入 | 2,500 | $21,445.9600 ...

執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的 | 交易性質 | 買入／賣 | 涉及的股份 | 已支付／已收取的 | 已支付或已 | 已支付或已 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 說明 | | 出 | 總數 | 總金額 | 收取的最高 | 收取的最低 | | | | | | | | | | | 價（H） | 價（L） | | J.P. Morgan | 2025 | 年 | 8 月 | 其他類別的 | 因全屬客戶主動發出且由客戶需求帶動的買賣 | 買入 | 14,000 | $119,587.0900 | $8.8800 | $8.4300 | | Securities | 13 日 | | | 證券 (例如: | 盤所產生的 Delta 1 產品的對沖活動 | | | | | | | PLC | | | | 股權互換) | | | | | | | | | | | | 其他類別的 | 因全屬客戶主動發出且由 ...

完 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | 有關證券的說 | 產品說明 | 交易性質 | 與衍生工具有 | 到期日或清結 | 參考價 | 已支付／已收取 | 交易後數額（包 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 明 | | | 關的參照證券 | 日 | | 的總金額 | 括與其訂有協議 | | | | | | | | 數目 | | | | 或達成諒解的任 | | | | | | | | | | | | 何人士的證券） | | J.P. Morgan | 2025年 | 8月13 | 衍生工具 | 其他類別產品 | 清結衍生工具合約 | 503,500 | 2026 年 7 月 2 | $8.5095 | $4,284,518.6500 | 8,982,503 | | Securities | 日 | | | | | | 日 | | | | | PLC | | | 衍生工具 | 其他類別產品 | 清結衍生工具合約 | 943 ...

Group 1 - The company, 康基医疗, and the offeror, Knight Bidco Limited, announced a privatization plan to allow the company to focus on long-term strategic decisions, including R&D investments and operational upgrades [1] - The proposed cancellation price is set at HKD 9.25 per share, representing a premium of approximately 21.7% over the closing price of HKD 7.6 as of the undisturbed date (June 30, 2025) [1] - The cancellation price also reflects a premium of about 29.7% over the average closing price of HKD 7.13 per share for the 120 trading days prior to the undisturbed date, and a premium of approximately 47.3% over the average closing price of HKD 6.28 per share for the 360 trading days prior [1] Group 2 - The privatization cash consideration amounts to approximately HKD 58.2 billion, and the offeror does not reserve the right to increase the cancellation price [2] - The offeror is backed by a consortium that includes alternative asset management company TPG [2] - 康基医疗 resumed trading today after being suspended since July 18 [2]

Group 1 - The privatization offer for Kangji Medical is led by Chairman Zhong Ming, TPG, and Qatar Investment Authority (QIA), with a proposed price of HKD 9.25 per share, valuing the company at approximately USD 1.4 billion [1][2] - The company has faced continuous pressure on its stock price and long-term liquidity issues, which have limited its ability to raise funds from the stock market [2] - The company was listed on the Hong Kong Stock Exchange in June 2020, with an initial offering price of HKD 13.88 per share, but the stock price had dropped to HKD 8.42 per share before the privatization announcement, indicating a significant decline [2] Group 2 - The offerors believe that maintaining the company's listing incurs administrative, compliance, and other costs, which provide limited benefits given the current market conditions and regulatory uncertainties [2] - Following the announcement of the privatization, the stock performance was relatively flat, with minor fluctuations observed on August 13, 2023 [2] - After the privatization, the Zhong couple will retain a 40% stake in the ultimate holding company, maintaining their position as the largest shareholders [1]

Group 1 - Kangji Medical (09997) resumed trading with a nearly 1% increase, announcing a privatization agreement with Knight Bidco Limited, which will make Kangji a wholly-owned subsidiary and delist from the Hong Kong Stock Exchange after completion [1] - Tencent Music (01698) opened high with over a 15% increase, reporting a 30% year-on-year increase in adjusted net profit for Q2 ending June 30, 2025, driven by high-quality growth in its online music business [1] - Mingyuan Cloud (00909) opened over 2% higher, announcing a cash acquisition of 100% equity in ASIOT Co., Ltd. for 700 million yen by its subsidiary MytePro Japan [1] Group 2 - Yuedu Group (00772) surged over 15%, reporting a 68.5% year-on-year increase in net profit for the first half of the year, with strong performance in IP for premium films and animations, and significant growth in the emerging short drama sector [2] - Minmetals Resources (01208) rose over 9%, with net profit increasing 15 times year-on-year, attributed to higher copper production and rising prices of copper, gold, silver, and zinc [2] - Beihai Kangcheng-B (01228) increased over 31%, announcing a strategic cooperation agreement with Baiyang Pharmaceutical for exclusive commercial services in promoting several products in mainland China, Hong Kong, and Macau [2] Group 3 - Zhonghui Biotech-B (02627) surged over 25%, as its vaccine product was included in the preliminary review list of the national commercial health insurance innovative drug catalog [2] - Gilead Sciences-B (01672) rose over 5%, announcing promising efficacy results for its candidate drug ASC47 in combination with teriparatide for obesity treatment in diet-induced obesity mouse studies [3] - Dongying Travel (06882) fell over 9%, issuing a profit warning with expected net profit of approximately 6 million HKD for the first half of 2025, down about 82% from 34 million HKD in the same period last year [3] Group 4 - Kodak (KODK.US) dropped 19.91% after reporting a shift from profit to loss in Q2, raising concerns about its ability to execute critical financing measures [4] - Niu Technologies (NIU.US) rose 11.69%, reporting a turnaround to profitability in Q2 and projecting Q3 revenue between 1.433 billion to 1.638 billion CNY, a year-on-year increase of 40% to 60% [4] - Huya (HUYA.US) increased by 4.53%, preparing to release its financial report, with a strong growth trajectory in gaming-related services [4] Group 5 - ON Running (ONON.US) rose 8.95%, reporting a 32% year-on-year increase in Q2 sales and projecting annual net sales of at least 2.91 billion Swiss francs, exceeding previous expectations [6] - Micron Technology (MU.US) increased by 3.26%, significantly raising its Q4 fiscal year 2025 revenue guidance to between 11.1 billion to 11.3 billion USD, with gross margin guidance improved to 44% to 45% [6]

智通财经获悉，康基医疗(09997)复牌高开逾5%，截至发稿，涨5.46%，报8.88港元，成交额797.87万港 元。 公告称，由于交易价格持续承压且股份流动性有限，公司从股权市场筹集资金能力受到限制。鉴于上述 情况，考虑到上市相关成本，公司维持上市地位裨益有限。同时，实施该建议将缓解公司短期财务表现 压力，促使公司更专注于需要额外资源配置战略目标，以实现未来可持续增长。 消息面上，康基医疗及其要约人Knight Bidco Limited联合公布，将以协议安排方式进行私有化。私有化 完成后，康基医疗将成为要约人的全资附属公司，并在联交所撤销上市。注销价格9.25港元，较最后交 易日收市价8.42港元溢价约9.9%。 本文源自：智通财经网 ...

Core Viewpoint - 康基医疗 is undergoing privatization through an agreement with Knight Bidco Limited, which will result in the company becoming a wholly-owned subsidiary and delisting from the Hong Kong Stock Exchange [1] Group 1: Stock Performance - 康基医疗's stock opened over 5% higher upon resumption of trading, currently up 5.46% at HKD 8.88, with a trading volume of HKD 7.9787 million [1] Group 2: Privatization Details - The privatization will occur at a cancellation price of HKD 9.25, representing a premium of approximately 9.9% over the last trading day's closing price of HKD 8.42 [1] - The company cited ongoing pressure on transaction prices and limited liquidity of shares as reasons for the privatization, which will alleviate short-term financial performance pressures [1] Group 3: Strategic Focus - The decision to privatize is aimed at reducing the costs associated with maintaining a public listing, as the benefits of remaining listed are deemed limited [1] - This move is expected to allow the company to concentrate on strategic goals that require additional resource allocation for sustainable future growth [1]

公告称，由于交易价格持续承压且股份流动性有限，公司从股权市场筹集资金能力受到限制。鉴于上述 情况，考虑到上市相关成本，公司维持上市地位裨益有限。同时，实施该建议将缓解公司短期财务表现 压力，促使公司更专注于需要额外资源配置战略目标，以实现未来可持续增长。 消息面上，康基医疗及其要约人Knight Bidco Limited联合公布，将以协议安排方式进行私有化。私有化 完成后，康基医疗将成为要约人的全资附属公司，并在联交所撤销上市。注销价格9.25港元，较最后交 易日收市价8.42港元溢价约9.9%。 智通财经APP获悉，康基医疗(09997)复牌高开逾5%，截至发稿，涨5.46%，报8.88港元，成交额797.87 万港元。 ...